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See Article, pages 730–735To have B or not to have B, that is the question?
Whether tis nobler in the mind to suffer
The slings and arrows of contagious fortune
Or to vaccinate against a sea of troubles
And by opposing end them. . .
Liberally adapted from William Shakespeare
Development of a sterilizing vaccine is the ultimate strategy
in the prevention of infectious diseases; treatment of established
disease pales by comparison in its relevance to global health.
Classic examples of vaccination-related disease eradication are
smallpox and polio. Hepatitis B could follow a similar global tra-
jectory given sufﬁcient resources and the will of national health
policies. The study of Yin-Hsian Ni, under the leadership of Ding
Shen Chen, in this issue of the Journal of Hepatology chronicles
how far we have come in the battle against hepatitis B. In
1984, when a universal vaccination program was initiated in
Taiwan, 10% of the population was hepatitis B surface antigen
(HBsAg) positive whereas the current rate among 3332 subjects
in the Ni et al. study is 0.9%. Similarly, the prevalence of anti-core
antibody (anti-HBc) has declined from 28% to 7% while the prev-
alence of protective surface antibody (anti-HBs) has risen from
24% to 56%. Serial 5-year interval analyses have shown that these
trends are progressive and it is anticipated that as fully vacci-
nated children age and continue to dilute the HBsAg carrier pop-
ulation, Taiwan will near-eradicate hepatitis B infection and serve
as a world model of what can be achieved when there is a
national will to face, manage and then prevent seemingly insur-
mountable health issues.
The achievements in Taiwan are all the more remarkable
given that only 50 years ago, hepatitis B was a disease by name
alone. There were no diagnostic assays, no observed particles,
no known sequences, no culture methods, no treatments and
no effective prevention strategies. This void began to ﬁll in the
early 060s with the serendipitous ﬁnding of a precipitin line in
agar that resulted from the interaction between the serum of aJournal of Hepatology 20
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ine. The aboriginal serum was part of a random panel that was
being tested for lipoprotein polymorphisms in the NIH laboratory
of Baruch Blumberg [1]. Early epidemiologic studies at NIH
revealed a strong and unexplained association of the ‘‘Australia
antigen’’ with leukemia. Subsequently, Blumberg moved to the
Fox Chase Cancer Center in Philadelphia where on the hypothesis
that the Australia antigen was genetically determined and had an
association with leukemia, he and Tom London studied patients
with Down’s syndrome who were known to have an inherited
predisposition to leukemia. An overall prevalence of 10% was
found among Down’s patients, initially supporting the genetic
hypothesis [2]. However, subsequent studies of institutionalized
versus non-institutionalized Down’s patients showed that the
association was not with the disease, but rather with conditions
of crowding and poor sanitation, providing the ﬁrst clue to the
infectious origin of this aboriginal antigen. The subsequent obser-
vation of antigen seroconversion in two Down’s syndrome
patients and a technologist in the Blumberg lab, coincident with
the onset of hepatitis, provided the deﬁnitive link between an
unexpected precipitin reaction and human disease and estab-
lished the ﬁrst hepatitis speciﬁc serologic assay [3]. Fred Prince
further deﬁned the association showing that it was speciﬁc for
serum and not infectious hepatitis [4]. Once a viral marker was
in place, hepatitis research became goal directed and accelerated
rapidly. Electron microscopy performed by Bayer and co-workers
[5] demonstrated an abundance of spherical and tubular particles
in Australia antigen positive specimens. Subsequently, Dane in
England [6] showed by immune-electron microscopy that the
spherical and tubular particles resided in complexes with larger
enveloped particles that proved to be the complete hepatitis B
virion and became known as the Dane particle. The antigen then
was renamed Hepatitis B Surface Antigen (HBsAg). Meanwhile,
Gerin and Purcell [7] used newly developed rate zonal ultracen-
trifugation to purify hepatitis B associated particles and to sort
the infectious Dane particles from non-infectious spheres and
tubules. These physical separations and chimpanzee infectivity
studies [8] set the stage for subsequent commercial vaccine
development by demonstrating that subunits of the virus were
immunogenic, but not infectious. By 1976, only 9 years after
the ﬁrst report that the Australia antigen was associated with12 vol. 57 j 715–717
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hepatitis, and only 13 years after the ‘‘aboriginal antigen’’ had set
the chain in motion, Maurice Hilleman and co-workers at Merck
manufactured a subunit, plasma-derived vaccine ready for clini-
cal trial. The clinical trial, conducted by the late Wolf Szmuness
and Cladd Stevens, was a classic in design and implementation.
It was a placebo-controlled efﬁcacy trial in high-risk male homo-
sexuals and provided unequivocal documentation of vaccine efﬁ-
cacy [9]. Indeed, among the 95% who responded to a full course of
vaccine, efﬁcacy was 100%. Hence, by 1982, there was a licensed
hepatitis B vaccine with the potential to eradicate this disease
throughout the world. However, the vaccine was too expensive
for developing nations where the risks of hepatitis B were, and
are, exceedingly high.
Taiwan became a focal point for large scale epidemiologic
studies of HBV prevalence, disease associations and prevention.
Palmer Beasley and Lu-Yu Hwang conducted a massive prospec-
tive study of the incidence of hepatocellular carcinoma (HCC)
among HBsAg positive and HBsAg negative subjects [10]. By fol-
lowing over 19,000 individuals, they showed that almost every
case of cirrhosis and HCC occurred in the HBsAg positive group
and that the relative risk of HCC was more than 200-fold greater
in HBV-infected individuals than in uninfected controls. Deﬁni-
tive epidemiologic links between HBV and HCC were also demon-
strated in South Africa by Michael Kew [11]. This unequivocal
association also suggested that the hepatitis B vaccine would
prevent HBV-related HCC and hence represent the ﬁrst cancer
vaccine. In a second series of studies, the Beasley team showed
that the offspring of HBsAg and HBeAg positive mothers had a
90% chance of becoming chronic HBV carriers and that this risk
could be reduced to 5% when hepatitis B immune globulin (HBIG)
and hepatitis B vaccine were administered sequentially immedi-
ately after birth [12]. This set the stage for the administration of
an HBIG-vaccine combination to children of known HBsAg
positive mothers and ultimately to universal HBV vaccination of
all newborns in Taiwan. The sequential 5-year analyses of
universal HBV vaccination that was initiated in Taiwan in 1984
and is reported herein by Ni et al., documents the predicted
efﬁcacy of universal vaccination in the prevention of hepatitis B
infection and its sequelae. The HBV/HBsAg carrier rate in Taiwan
has decreased ten-fold to less than 1%, not only protecting the
vaccine recipients, but also preventing a huge number of
secondary infections. Importantly, there is no trend to increased
prevalence with age indicating the prolonged protective effect
of vaccine even in the absence of booster inoculations. The rate
of occult HBV infection, characterized by the presence of HBV
DNA in the absence of HBsAg has declined from 0.8% to 0.1%
(p = 0.003) over this same study interval. Although not measured
in this study, other studies have already documented declining
rates of HCC in Taiwan since the inception of universal vaccina-
tion [13].
It has been known since the original HBV vaccine trails in Tai-
wan that there is a small, but ﬁnite proportion of HBV vaccine
recipients who nonetheless show serologic or molecular evi-
dence of HBV infection. Since the primary mode of HBV transmis-
sion in HBV endemic regions is from an HBsAg and HBeAg
positive mother to her offspring, the most likely reason for vac-
cine failure is that the fetus was infected in utero and that the
infection was well established before vaccine was administered;
this has suggested a strategy wherein HBsAg, and especially
HBeAg, positive mothers would be given antiviral agents during
pregnancy. A second reason for vaccine failure could be a very716 Journal of Hepatology 201high viral load that would overwhelm vaccine efﬁcacy. Third, a
given individual might harbor a vaccine escape mutant. While
this is a serious theoretical concern, there is little scientiﬁc evi-
dence that vaccine escape mutants have entered the general pop-
ulation. The emergence of such mutants would presage that the
vaccine would become less effective over time, but there is no
evidence for loss of efﬁcacy over the 25 year duration of the Tai-
wanese study.
What then are the impediments to the global eradication of
hepatitis B infection? These impediments do not reside in the sci-
entiﬁc arena. Indeed, the science of recombinant HBV vaccine
development is very advanced and it is probable that future for-
mulations will provide only marginal increases in efﬁcacy,
though they might provide beneﬁt through ease of administra-
tion and less frequent dosing. Further, the universal vaccination
program in Taiwan has not only established vaccine efﬁcacy,
but has provided proof of principle that HBV vaccine can be effec-
tively administered to virtually all neonates in a given popula-
tion, can markedly diminish the HBV carrier rate and can break
the treacherous cycle of maternal–fetal transmission that perpet-
uates the carrier state and recycles virus into the next generation.
The concomitant of such vaccine efﬁcacy is the prevention of
chronic hepatitis, cirrhosis and HCC, all of which have been doc-
umented. With the Taiwan model in place, there is new impetus
to attack the ﬁnal hurdles to a global vaccination strategy,
namely ﬁnancial resources and the will of impoverished nations
to make this a national health priority. More progress has been
made in this socio-economic arena than would have seemed
imaginable only a decade ago. In a unique and truly remarkable
collaboration between the World Health Organization (WHO),
UNICEF, the World Bank, the Bill and Melinda Gates Foundation,
donor governments, developing countries, international develop-
ment and ﬁnance organizations and the pharmaceutical industry,
the Global Alliance for Vaccines and Immunization (GAVI) was
founded in 1999. Statistics from WHO/GAVI indicate that each
year 1.7 million children in developing countries die from a vac-
cine-preventable disease; in dramatic and sobering mathematics,
this represents one life every 20 seconds. These deaths are from a
variety of vaccine preventable diseases including tuberculosis,
diphtheria, tetanus, pertussis, measles, polio, pneumococcal
pneumonia, and rotavirus-induced diarrhea. Deaths from hepati-
tis B are less acute, but perhaps equally devastating over a life-
time. GAVI has thus far fostered immunization of 326 million
children and has set a goal to immunize 243 million additional
children from 2011 to 2015 predicting this will prevent 4 million
future deaths. 65 countries have now introduced a pentavalent
vaccine that protects against diphtheria, tetanus, pertussis, hepa-
titis B, and hemophilus inﬂuenza. Hence it is apparent that hep-
atitis B vaccination can be applied on a global scale and can
achieve efﬁcacy in developing countries that are willing to part-
ner with GAVI to protect their populations from infant and
long-term mortality. The complete eradication of hepatitis B will
take several more generations but all the pieces are in place and
the unimaginable is now the conceivable.Conﬂict of interest
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